RecruitingNot ApplicableNCT06278506

Resection or Ablation of Small Kidney Tumors

Resection or Ablative Treatment of Small Renal Tumors, a Multicenter Randomized Clinical Trial

Sponsor

Karolinska University Hospital

Enrollment

300 participants

Start Date

Jan 31, 2024

Study Type

INTERVENTIONAL

Conditions

Kidney Cancer

Summary

Ablative treatments are believed to have a lower rate of complications, shorter hospital stays, and fewer interventions with benign PAD compared to partial nephrectomies in small kidney cancer lesions. The purpose of the study is to compare complications, the frequency of residual tumors, impact on kidney function, differences in quality of life, and health economic factors in a randomised study. We will also compare the oncological outcomes, including survival and recurrence of kidney cancer.

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing two treatments for small kidney tumors (3 cm or less): surgical removal (partial nephrectomy) versus ablation (using heat or cold to destroy the tumor without cutting it out). The goal is to find out which approach produces better long-term outcomes. **You may be eligible if...** - You are between 18 and 99 years old - You have a small, primary kidney tumor (3 cm or less, Stage T1a) with no signs of spread - Your tumor is suitable for both surgery and ablation - Your tumor biopsy confirms it is malignant (cancerous) with a grade of I-III - You are healthy enough for both surgical and ablation treatment options **You may NOT be eligible if...** - There are imaging signs of cancer spread (metastasis) - You have multiple kidney tumors at the same time - Your tumor biopsy shows a very aggressive grade (IV) or sarcomatoid growth - You have had another metastatic cancer in the past 5 years - You are unable to make an informed decision to participate Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.